Compare Stocks: ARVN, PHVS, VERA, and VCEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$9.36 +3.8%	$8.37	$6.97 ▼ $14.51	$604.24M	1.71	895,748 shs	951,751 shs
PHVS Pharvaris	$36.27 -0.3%	$34.17	$20.65 ▼ $36.93	$2.37B	-2.31	569,860 shs	515,438 shs
VCEL Vericel	$42.68 +1.4%	$44.63	$28.95 ▼ $49.32	$2.19B	1.06	468,538 shs	647,127 shs
VERA Vera Therapeutics	$32.28 +3.3%	$36.32	$21.15 ▼ $56.05	$2.33B	0.92	2.09 million shs	1.29 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	+4.35%	+15.27%	+2.97%	+31.83%
PHVS Pharvaris	0.00%	+3.22%	+9.05%	+22.20%	+57.70%
VCEL Vericel	0.00%	-3.44%	-5.24%	+22.89%	+20.70%
VERA Vera Therapeutics	0.00%	+2.06%	-11.20%	-5.17%	+46.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$9.36 +3.8%	$8.37	$6.97 ▼ $14.51	$604.24M	1.71	895,748 shs	951,751 shs
PHVS Pharvaris	$36.27 -0.3%	$34.17	$20.65 ▼ $36.93	$2.37B	-2.31	569,860 shs	515,438 shs
VCEL Vericel	$42.68 +1.4%	$44.63	$28.95 ▼ $49.32	$2.19B	1.06	468,538 shs	647,127 shs
VERA Vera Therapeutics	$32.28 +3.3%	$36.32	$21.15 ▼ $56.05	$2.33B	0.92	2.09 million shs	1.29 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	+4.35%	+15.27%	+2.97%	+31.83%
PHVS Pharvaris	0.00%	+3.22%	+9.05%	+22.20%	+57.70%
VCEL Vericel	0.00%	-3.44%	-5.24%	+22.89%	+20.70%
VERA Vera Therapeutics	0.00%	+2.06%	-11.20%	-5.17%	+46.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.45	Hold	$14.17	51.35% Upside
PHVS Pharvaris	2.86	Moderate Buy	$51.08	40.82% Upside
VCEL Vericel	2.57	Moderate Buy	$58.40	36.83% Upside
VERA Vera Therapeutics	2.86	Moderate Buy	$81.15	151.41% Upside

Current Analyst Ratings Breakdown

Latest ARVN, PHVS, VERA, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$34.00
8/14/2026	PHVS Pharvaris	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00
8/14/2026	PHVS Pharvaris	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D)
8/13/2026	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/13/2026	PHVS Pharvaris	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight
8/13/2026	PHVS Pharvaris	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	PHVS Pharvaris	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$51.00 ➝ $52.00
8/13/2026	PHVS Pharvaris	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$74.00 ➝ $75.00
8/12/2026	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$125.00 ➝ $90.00
8/11/2026	VERA Vera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$84.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$262.60M	2.30	N/A	N/A	$8.71 per share	1.07
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.35 per share	N/A
VCEL Vericel	$276.26M	7.91	$0.56 per share	76.83	$7.23 per share	5.90
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$5.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$80.80M	$0.10	93.61	N/A	N/A	2.94%	1.91%	1.29%	11/4/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
VCEL Vericel	$16.52M	$0.47	90.81	50.81	N/A	7.91%	6.91%	5.02%	11/5/2026 (Estimated)
VERA Vera Therapeutics	-$299.61M	-$5.86	N/A	N/A	N/A	N/A	-84.13%	-66.79%	11/4/2026 (Estimated)

Latest ARVN, PHVS, VERA, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/10/2026	Q2 2026	VERA Vera Therapeutics	-$1.58	-$1.52	+$0.06	-$1.52	$1.28 million	N/A
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million
7/30/2026	Q2 2026	VCEL Vericel	-$0.0289	$0.04	+$0.0689	$0.04	$72.70 million	$77.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	7.91	7.91
PHVS Pharvaris	N/A	11.94	11.94
VCEL Vericel	N/A	5.04	4.69
VERA Vera Therapeutics	0.18	10.92	10.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
PHVS Pharvaris	N/A
VCEL Vericel	N/A
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	7.30%
PHVS Pharvaris	11.84%
VCEL Vericel	7.60%
VERA Vera Therapeutics	15.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	64.52 million	59.81 million	Optionable
PHVS Pharvaris	30	65.41 million	57.66 million	Not Optionable
VCEL Vericel	300	51.21 million	47.32 million	Optionable
VERA Vera Therapeutics	40	72.06 million	60.61 million	Optionable

ARVN, PHVS, VERA, and VCEL Headlines

Recent News About These Companies

Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move?

August 19, 2026 | kalkinemedia.comK

J.P. Morgan Sticks to Their Buy Rating for Vera Therapeutics (VERA)

August 19, 2026 | theglobeandmail.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Moderate Buy" by Analysts

August 19, 2026 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts

August 19, 2026 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Earns "Neutral" Rating from Wedbush

August 19, 2026 | americanbankingnews.com

Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA

August 18, 2026 | marketbeat.com

Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy

August 17, 2026 | seekingalpha.com

Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA)

August 17, 2026 | marketbeat.com

Q3 EPS Forecast for Vera Therapeutics Boosted by Analyst

August 16, 2026 | americanbankingnews.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's Why

August 14, 2026 | marketbeat.com

HC Wainwright Has Positive Estimate for VERA Q3 Earnings

August 14, 2026 | marketbeat.com

HC Wainwright Lowers Vera Therapeutics (NASDAQ:VERA) Price Target to $90.00

August 14, 2026 | americanbankingnews.com

Wedbush Issues Pessimistic Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

August 13, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Clinigence Holdings (NUTX), Vera Therapeutics (VERA) and Solid Biosciences (SLDB)

August 12, 2026 | theglobeandmail.com

Vera Therapeutics (NASDAQ:VERA) Given New $90.00 Price Target at HC Wainwright

August 12, 2026 | marketbeat.com

E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA

August 12, 2026 | marketbeat.com

Wedbush Lowers Vera Therapeutics (NASDAQ:VERA) Price Target to $34.00

August 11, 2026 | marketbeat.com

Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

August 10, 2026 | markets.businessinsider.com

Vera Therapeutics (NASDAQ:VERA) Announces Quarterly Earnings Results

August 10, 2026 | marketbeat.com

Silence Therapeutics shares surge ahead of divesiran Phase 2 results call

August 10, 2026 | finance.yahoo.com

Dimensional Fund Advisors LP Decreases Stock Position in Vera Therapeutics, Inc. $VERA

August 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARVN, PHVS, VERA, and VCEL Company Descriptions

Arvinas NASDAQ:ARVN

$9.36 +0.34 (+3.77%)

As of 08/21/2026 04:00 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Pharvaris NASDAQ:PHVS

$36.27 -0.12 (-0.33%)

As of 08/21/2026 04:00 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Vericel NASDAQ:VCEL

$42.68 +0.57 (+1.35%)

As of 08/21/2026 04:00 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vera Therapeutics NASDAQ:VERA

$32.28 +1.02 (+3.26%)

As of 08/21/2026 04:00 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, PHVS, VERA, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, PHVS, VERA, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, PHVS, VERA, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARVN, PHVS, VERA, and VCEL Company Descriptions

Arvinas NASDAQ:ARVN

Pharvaris NASDAQ:PHVS

Vericel NASDAQ:VCEL

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, PHVS, VERA, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, PHVS, VERA, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, PHVS, VERA, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARVN, PHVS, VERA, and VCEL Company Descriptions

Arvinas NASDAQ:ARVN

Pharvaris NASDAQ:PHVS

Vericel NASDAQ:VCEL

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools